Macrolides: Mode of Action, Mechanism of Resistance

A young adult has a dry cough, low fever, and a chest x-ray that looks worse than the patient feels: classic "walking" pneumonia. The team does not reach for a penicillin, because the likely culprit, Mycoplasma pneumoniae, has no cell wall for a beta-lactam to attack.

Instead they prescribe azithromycin. It works because macrolides ignore the cell wall entirely and jam the bacterial ribosome, the protein factory every bacterium depends on.

That single idea, hitting the ribosome instead of the wall, explains what macrolides treat, why they are the go-to backup when penicillin cannot be used, and how bacteria fight back.

What are macrolides?

Macrolides are a family of bacteriostatic antibiotics that block bacterial protein synthesis by binding the 50S subunit of the ribosome. The group includes erythromycin, clarithromycin, azithromycin, roxithromycin, dirithromycin, and telithromycin.

Erythromycin, the first macrolide, was introduced in 1952 as an alternative to penicillin, and it was originally isolated from the soil bacterium Saccharopolyspora erythraea (formerly Streptomyces erythreus).

Macrolides are active mainly against gram-positive bacteria (though not enterococci) and, importantly, against the atypical and intracellular pathogens that beta-lactams miss, such as Mycoplasma, Chlamydia, and Legionella.

Why macrolides matter

Macrolides fill two clinical roles that make them worth understanding in detail.

1. First, they are the standard alternative for patients who are allergic to penicillin, covering many of the same gram-positive infections.
2. Second, they reach pathogens that cell-wall drugs cannot touch, which makes them first-line for atypical pneumonia, whooping cough (pertussis), and chlamydial infection.

Knowing how they work explains their spectrum, their well-known drug interactions and heart-rhythm caution, and the resistance pattern (MLSb) that ties them to a laboratory test you will meet on the bench, the D-test.

Structure

Macrolides are built around a large macrocyclic lactone ring, which is where the class gets its name, with one or more deoxy sugars attached to it.

Figure one: Structure of macrolides

They are classified by the size of that ring: 14-membered (erythromycin, clarithromycin, roxithromycin), 15-membered (azithromycin, an azalide, because a nitrogen is inserted into the ring), and 16-membered (spiramycin, josamycin). The ketolides, such as telithromycin, are semi-synthetic derivatives of the 14-membered ring designed to overcome some macrolide resistance.

Classification and members

Mode of action of macrolides

Macrolides bind reversibly to the 50S ribosomal subunit, at a site in the 23S ribosomal RNA within the exit tunnel through which the growing peptide leaves the ribosome. By blocking that tunnel they stop the elongation of the protein chain: the 14-membered macrolides block translocation of peptidyl-tRNA, and the current understanding is that macrolides more broadly cause the premature dissociation of peptidyl-tRNA from the ribosome during elongation.

The result is that the bacterium cannot complete its proteins, so it stops growing. Macrolides are therefore bacteriostatic at usual doses, though they can be bactericidal at high concentrations against some highly susceptible organisms.

Figure two: Mode of Action of Macrolides

Macrolides are one of the antibiotic classes that act by inhibiting protein synthesis, working on the 50S subunit. Read these articles to see where this sits among the five mechanisms of action of antibiotics, and how the 50S drugs differ from the 30S drugs like tetracyclines.

Mechanism of resistance to macrolides

The ways bacteria resist macrolides are specific examples of the general mechanisms of antibiotic resistance: target modification, active efflux, and enzymatic inactivation.

Target modification (the main mechanism). Bacteria carrying erm genes produce an enzyme (a methyltransferase) that methylates the 23S rRNA at the macrolide binding site. Because that site is shared by macrolides, lincosamides (clindamycin), and streptogramin B, a single change makes the bacterium resistant to all three at once. This is the MLSb phenotype, and it can be constitutive (always on) or inducible (switched on only when the bacterium meets a macrolide). Inducible MLSb is why a strain can look clindamycin-susceptible in the lab yet fail in the patient, and it is exactly what the D-test detects. Point mutations in the 23S rRNA or in ribosomal proteins L4 and L22 can also alter the target.

Active efflux. Pumps remove the drug before it can bind. The mef genes (major facilitator superfamily) pump out 14- and 15-membered macrolides, and the msr genes (ABC superfamily) add efflux of streptogramin B. Efflux is a common cause of macrolide resistance in streptococci and staphylococci.

Enzymatic inactivation. Some bacteria make enzymes (esterases, phosphotransferases, glycosyltransferases) that chemically inactivate the drug. These are often plasmid-encoded.

Clinical uses

Macrolides are used for community-acquired and atypical pneumonia (Mycoplasma, Chlamydophila, Legionella), whooping cough (pertussis), chlamydial genital infection, diphtheria and pertussis prophylaxis, some streptococcal and skin infections in penicillin-allergic patients, and, for clarithromycin, as part of Helicobacter pylori eradication and in Mycobacterium avium complex disease.

Azithromycin's very long half-life allows short, convenient courses.

Side effects and interactions

The most common problem is gastrointestinal upset, because erythromycin stimulates motilin receptors in the gut and speeds motility (an effect occasionally used deliberately as a prokinetic). Macrolides can prolong the QT interval, so they carry a risk of dangerous arrhythmias, especially combined with other QT-prolonging drugs.

Erythromycin and clarithromycin also inhibit the liver enzyme CYP3A4, which raises the levels of many co-administered drugs; azithromycin has far fewer of these interactions, one reason it is often preferred.

How to remember

The three you must know, "clarithro, azithro, erythro," are the everyday macrolides; azithromycin is the azalide (15-membered, long half-life, single-dose convenience).

Where they act: macrolides are 50S drugs. This pairs with the mnemonic in the Antibiotics Mechanism of Action article, where the 50S inhibitors are chloramphenicol, clindamycin, erythromycin (macrolides), and linezolid, and the 30S inhibitors are aminoglycosides and tetracyclines.

MLSb in one line: one methylation (erm) knocks out Macrolides, Lincosamides, and Streptogramin B together. That shared binding site is why clindamycin can fail even when it looks susceptible, and why the D-test exists.

Where students actually get confused

Macrolides (50S) versus tetracyclines (30S). Both inhibit protein synthesis, but on different ribosomal subunits. Macrolides block the exit tunnel on the 50S; tetracyclines block tRNA entry on the 30S.

Bacteriostatic, not bactericidal. Macrolides usually stop growth rather than kill, though they can be cidal at high concentration against susceptible organisms. "Static" does not mean weak; the host immune system finishes the job.

Erythromycin's GI upset is not an allergy. It is a direct effect on gut motilin receptors, not a hypersensitivity reaction, so switching to azithromycin (which does this far less) often solves it.

Inducible versus constitutive MLSb. A strain can test clindamycin-susceptible but carry inducible resistance that appears during treatment. The D-test unmasks it. This is the single most tested point about macrolide resistance.

Azithromycin is not just "another erythromycin." Its 15-membered azalide structure gives it a much longer half-life, better tissue penetration, and far fewer CYP3A4 interactions.

Key exam facts

References

1. Mazzei T, Mini E, Novelli A, Periti P (1993). Chemistry and mode of action of macrolides. Journal of Antimicrobial Chemotherapy. 31(Suppl C): 1-9.
2. Bryskier A, Bergogne-Berezin E (2005). Macrolides. In Antimicrobial Agents. American Society for Microbiology. pp. 475-526.
3. Fyfe C, Grossman TH, Kerstein K, Sutcliffe J (2016). Resistance to macrolide antibiotics in public health pathogens. Cold Spring Harbor Perspectives in Medicine. 6(10): a025395.
4. Vazquez-Laslop N, Mankin AS (2018). How macrolide antibiotics work. Trends in Biochemical Sciences. 43(9): 668-684.
5. Leclercq R (2002). Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clinical Infectious Diseases. 34(4): 482-492.